These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Tolvaptan for the treatment of hyponatremia and congestive heart failure. Ferrer E Drugs Today (Barc); 2010 Mar; 46(3):163-71. PubMed ID: 20467590 [TBL] [Abstract][Full Text] [Related]
8. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953 [TBL] [Abstract][Full Text] [Related]
9. Tolvaptan for the treatment of heart failure: a review of the literature. Ambrosy A; Goldsmith SR; Gheorghiade M Expert Opin Pharmacother; 2011 Apr; 12(6):961-76. PubMed ID: 21401442 [TBL] [Abstract][Full Text] [Related]
10. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C; Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979 [TBL] [Abstract][Full Text] [Related]
11. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure. Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113 [TBL] [Abstract][Full Text] [Related]
12. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Saito T; Ishikawa S; Abe K; Kamoi K; Yamada K; Shimizu K; Saruta T; Yoshida S J Clin Endocrinol Metab; 1997 Apr; 82(4):1054-7. PubMed ID: 9100572 [TBL] [Abstract][Full Text] [Related]
13. Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT). Verbalis JG; Ellison H; Hobart M; Krasa H; Ouyang J; Czerwiec FS; Am J Kidney Dis; 2016 Jun; 67(6):893-901. PubMed ID: 26874645 [TBL] [Abstract][Full Text] [Related]
14. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of vasopressin-receptor antagonists in heart failure. Izumi Y; Miura K; Iwao H J Pharmacol Sci; 2014; 124(1):1-6. PubMed ID: 24401675 [TBL] [Abstract][Full Text] [Related]
16. Arginine-Vasopressin Receptor Blocker Conivaptan Reduces Brain Edema and Blood-Brain Barrier Disruption after Experimental Stroke in Mice. Zeynalov E; Jones SM; Seo JW; Snell LD; Elliott JP PLoS One; 2015; 10(8):e0136121. PubMed ID: 26275173 [TBL] [Abstract][Full Text] [Related]
17. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review. Nemerovski C; Hutchinson DJ Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957 [TBL] [Abstract][Full Text] [Related]
18. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Cárdenas A; Ginès P; Marotta P; Czerwiec F; Oyuang J; Guevara M; Afdhal NH J Hepatol; 2012 Mar; 56(3):571-8. PubMed ID: 22027579 [TBL] [Abstract][Full Text] [Related]
19. Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan. Friedman B; Cirulli J J Crit Care; 2013 Apr; 28(2):219.e1-12. PubMed ID: 22884529 [TBL] [Abstract][Full Text] [Related]